**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 85939

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Progress of ulcerative colitis patients during the COVID-19 pandemic**

Suda T *et al*. Progress of UC during COVID-19 pandemic

Toshikuni Suda, Morio Takahashi, Yasumi Katayama, Koichi Soga, Ikuhiro Kobori, Yumi Kusano, Masaya Tamano

**Toshikuni Suda, Yasumi Katayama, Koichi Soga, Ikuhiro Kobori, Yumi Kusano, Masaya Tamano,** Division of Gastroenterology, Dokkyo Medical University Saitama Medical Center, Saitama 343-8555, Japan

**Morio Takahashi,** Division of Gastroenterology, Morio Clinic, Saitama 343-0808, Japan

**Author contributions:** Suda T recruited patients and wrote the paper; Takahashi M designed the study and analyzed data; Soga K revised the manuscript; Kobori I and Kusano Y provided clinical advice; and Tamano M and Katayama Y supervised the study.

**Corresponding author: Toshikuni Suda, Doctor, MD, PhD, Doctor, Instructor, Staff Physician,** Division of Gastroenterology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-Koshigaya, Koshigaya-Shi, Saitama 343-8555, Japan. toshikuni.suda@gmail.com

**Received:** May 24, 2023

**Revised:** June 30, 2023

**Accepted:** July 25, 2023

**Published online:** August 16, 2023

**Abstract**

BACKGROUND

We have previously demonstrated that the first wave of the coronavirus disease 2019 (COVID-19) pandemic caused exacerbations in ulcerative colitis (UC) patients, probably through psychological and physical stress. However, successive waves of the COVID-19 pandemic continuously followed the first. The effects of this chronic stress on the disease condition in UC patients are of interest.

AIM

To clarify the effect of chronic stress from COVID-19 on disease condition in patients aggravated after the first wave.

METHODS

Our previous study investigated 289 consecutive UC outpatients treated in one center during March and April 2020, the period of the first wave of the COVID-19 pandemic. In this study, an identical group of 289 UC patients was evaluated using UC-disease activity index (UC-DAI), endoscopic mucosal appearance score, and Matts pathological grade scoring.

RESULTS

Of the 289 UC patients included in the study in 2020, 10 patients dropped out as of 2021 and another 11 patients dropped out as of 2022, making three groups for 2020, 2021 and 2022. No significant differences in characteristics were found among the three groups. UC-DAI scores had aggravated during the period of the first wave of the COVID-19 pandemic, but significantly recovered in 2021 and remained stablein 2022. Matts grade scores significantly recovered in 2021 from those in 2020 and remained stablein 2022.

CONCLUSION

Disease activity of UC patients recovered in 2021 and remained stable in 2022, aggravated by the stress of the first wave of COVID-19 in 2020 despite persistence of the pandemic.

**Key Words:** Ulcerative colitis; COVID-19; Exacerbation; Stress; Ulcerative colitis disease activity index; Matts grade

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Suda T, Takahashi M, Katayama Y, Soga K, Kobori I, Kusano Y, Tamano M. Progress of ulcerative colitis patients during the COVID-19 pandemic. *World J Clin Cases* 2023; 11(23): 5462-5467

**URL:** <https://www.wjgnet.com/2307-8960/full/v11/i23/5462.htm>

**DOI:** https://dx.doi.org/10.12998/wjcc.v11.i23.5462

**Core Tip:** Previously, we demonstrated that the first wave of coronavirus disease 2019 (COVID-19) pandemic caused exacerbation in ulcerative colitis (UC) patients. Impact of the successive waves of the pandemic is of interest. We adopted the identical group of patients who were included in our previous study indicating the impact of the first wave in 2020. Disease activity of UC patients, aggravated by the stress of the first wave of COVID-19 in 2020, recovered significantly in 2021 and remained stable in 2022, despite persistence of the pandemic.

**INTRODUCTION**

We have previously demonstrated that the first wave of the coronavirus disease 2019 (COVID-19) pandemic caused exacerbation of ulcerative colitis (UC) in patients, presumably through psychological and physical stress. Our findings also indicated that stress from COVID-19 did not directly influence the condition of UC patients, but provided a psychological background against which specific stress could act. Patients felt that everyday stress, such as the disease itself, work, or home life, directly induced exacerbation of the disease, which was probably enhanced by the background mood of anxiety about being sick and a sense of limitations on everyday activities in communications with others[[1](#_ENREF_1)]. The pandemic continued throughout 2021, but the Japanese government ended the State of Emergency declaration and loosed restrictions on movement for people (including lock-downs) for economic and political reasons[2-4]. Inflammatory bowel disease (IBD) doctors would be able to implement preventive measures to avoid disease exacerbations if they become aware of the risks of exacerbation in advance. Preventive measures can include increasing 5-aminosalicylic acid (5-ASA) administration, providing topical formulations (5-ASA enema, prednisolone enema, budesonide form enema, *etc.*) and so on. IBD doctors are therefore concerned about the effects of successive waves of the COVID-19 pandemic on UC exacerbation. In this study, we followed-up the same group of UC patients included in the last study, in which these patients had shown significant exacerbation with the first wave of the COVID-19 pandemic[[1](#_ENREF_1)]. Wintjens *et al*[5] indicated that fresh, acute stress in particular has a stronger influence than continuous stress on UC patients in the form of outcomes such as exacerbations.

We evaluated whether the condition of UC would stay aggravated during the second and subsequent waves of COVID-19 or whether recovery would be achieved and remain after some point. We therefore assessed patient conditions in 2021 and 2022, when the 2nd through 8th waves were experienced in Japan, using UC disease indices for symptoms, endoscopic mucosal appearance, and pathological scoring.

**MATERIALS AND METHODS**

***Patients***

Our original study included a total of 289 consecutive UC outpatients from a single center during March and April 2020, representing the period of the first wave of the COVID-19 pandemic. This same group of 289 UC patients visiting the clinic regularly was included in the present study. Of the 289 UC patients included in the 2020 study, 10 patients dropped out as of 2021 and another 11 patients dropped out as of 2022, making three groups for 2020, 2021 and 2022. The UC activity of these patients continued to be evaluated in March and April of both 2021 and 2022. The UC activity of patients was scored using the UC disease activity index (UC-DAI), including endoscopic mucosal appearance, and Matts pathological grading, as described below.

***UC-DAI***

The UC-DAI is defined as the total of scores for stool frequency (normal, 0; 1-2 stools/day more than normal, + 1; 3-4 stools/day more than normal, + 2; and > 4 stools/day more than normal, + 3), rectal bleeding (none, 0; blood visible with stool less than half the time, + 1; blood visible with stool half the time or more, + 2; and passage of blood only, + 3), physician rating of disease activity (normal, 0; mild, + 1; moderate, + 2; and severe, + 3), and physician rating of mucosal appearance (normal, 0; mild friability, + 1; moderate friability, + 2; and exudation, spontaneous bleeding, + 3)[6].

***Matts UC pathological grading***

Biopsy samples were acquired during endoscopic examination of the cecum, ascending colon, transverse colon, sigmoid colon and rectum. Each sample was assessed using the following standard: Grade 1, normal appearance; grade 2, some infiltration of the mucosa or lamina propria by either round cells or polymorphs; grade 3, marked cellular infiltration of the mucosa, lamina propria, and submucosa; grade 4, presence of crypt abscesses, with marked infiltration of all layers of the mucosa; and grade 5, ulceration, erosion, or necrosis of the mucosa, with cellular infiltration of some or all layers of the mucosa[7].

This retrospective study was reviewed and approved by the Ethics Committee at Dokkyo Medical University Saitama Medical Center (approval No. 20100). Written, informed consent was obtained from all UC patients prior to enrolment. This study conformed to the ethical guidelines of the 2008 Declaration of Helsinki. All data were obtained from clinical records, which were written on the day each patient visited the facility.

***Statistical analysis***

Quantitative data are presented as mean ± SD. Discrete variables are presented as median and range. For statistical comparisons of UC-DAI, including endoscopic appearance and Matts pathological grade score, between the years of 2020, 2021 and 2022, we used paired *t*-tests. Values of *P* < 0.05 were considered significant.

**RESULTS**

***Characteristics***

Of the 289 UC patients included in the 2020 study, 10 patients dropped out as of 2021 and another 11 patients dropped out as of 2022, making three groups for 2020, 2021 and 2022. For two years, a total of 21 patients dropped out from the original group of patients; otherwise, the groups were identical. Table 1 shows the characteristics of the study participants (including age, weight, height, smoking rate, sex, pancolitis rate, and medication) in 2020 at entry, and in 2021 and 2022 during repeated waves of the COVID-19 pandemic (Table 1).

***Pharmacotherapies***

Table 2 shows the pharmacotherapies used by the patients included in 2020 at entry, as well as in 2021 and 2022 (Table 2).

***UC-DAI***

Mean UC-DAI (± SD) during the first wave of the pandemic was 1.07 ± 1.62, compared to 0.63 ± 1.29 in March and April 2021, and 0.48 ± 1.05 in March and April 2022. UC-DAI scores thus showed a significant recovery in 2021 and remained stable in 2022.

Although patients suffered repeated waves of the COVID-19 pandemic, UC-DAI recovered quickly after the first wave (2020 *vs* 2021, *P* = 0.0003; 2020 *vs* 2022, *P* = 0.000; 2021 *vs* 2022, *P* = 0.1755) (Figure 1A).

***Matts grade score***

Mean Matts grade score during the first wave of the pandemic was 2.80 ± 0.86, compared to 2.59 ± 0.90 in March and April 2021 and 2.47 ± 0.91 in March and April 2022. Matts grade scores significantly recovered in 2021 from that of 2020 and remained stable thereafter (2020 *vs* 2021, *P* = 0.0074; 2020 *vs* 2022, *P* = 0.0001; 2021 *vs* 2022, *P* = 0.1652) (Figure 1B).

**DISCUSSION**

We have previously demonstrated that UC patients regularly visiting our clinic experienced exacerbation of UC after the first wave of the COVID-19 pandemic in 2020[[1](#_ENREF_1)]. As of March 2021, Japan was experiencing its 8th wave of COVID-19[2]. The disease conditions of patients from the 2nd wave on are of interest. We retrospectively evaluated clinical conditions using the UC-DAI, as well as mucosal condition from endoscopic appearance and pathological Matts grading, which is reliably used worldwide to evaluate mucosal inflammation in UC patients[8,9]. Disease activity in UC patients worsened significantly with the first wave of the COVID-19 pandemic, but recovered significantly after the 2nd wave and remained stable thereafter up to the 7th wave (July and August 2022)[2]. Our previous report indicated that the condition of UC patients exacerbated with the first wave of COVID-19 largely through economic and social limitations on daily life, as well as uncertainty over when the pandemic would be over[[1](#_ENREF_1)]. The pandemic remains ongoing in Japan, but disease exacerbation did not continue. Conversely, patients recovered soon after the second wave. The possibilities include either that the pandemic ceased to represent a major stressor or patient sensitivity to the stress became dulled. Robillard *et al*[10] reported that people expressed strong stress at the beginning of the pandemic, but this stress decreased over time and recovered to pre-pandemic levels by 2 mo after the declaration of a State of Emergency. This was considered to represent formation of a kind of self-defense. The majority of IBD patients may remain in remission thanks to new pharmacological agents such as biologics and JAK inhibitors. This enables medical practitioners to treat IBD patients in outpatient-based facilities. More attention is therefore being given to maintaining remission rather than treating severe cases[[11](#_ENREF_8)]. To keep patients in remission, the present study indicated that IBD doctors should be aware of the stress situation of patients, and should anticipate the effects of stress on near-future disease activities to control and prevent flares. Upgrading remission treatments involves measures such as increasing doses of 5-ASA, adding extra topical therapy, and using systemic administration of steroid and biological agents as necessary. Of course, the additional risks should always be taken into consideration. IBD doctors must always strive to balance the benefits and risks.

**CONCLUSION**

We have demonstrated that the disease activity of UC patients as assessed by UC-DAI, endoscopy and pathology (Matts grading), which was exacerbated in 2020 with the first wave of the COVID-19 pandemic, recovered significantly in 2021 and remained stable in 2022, despite the persistence of the pandemic. In order to keep patients in remission, IBD doctors should anticipate the risk of flares according to these findings and upgrade treatments in advance.

**ARTICLE HIGHLIGHTS**

***Research background***

Previously, we reported that patients with ulcerative colitis (UC) had the worst symptoms during the coronavirus disease 2019 (COVID-19) pandemic.

***Research motivation***

The COVID-19 pandemic continued in 2021 and 2022.

***Research objectives***

We investigated whether people with UC had changes in symptoms in 2021 and 2022.

***Research methods***

Patients with UC included in previous studies were compared using UC-disease activity index (UC-DAI) and the Matts grade score.

***Research results***

Both UC-DAI and Matts grade scores fell from 2020 to 2021 and did not rise in 2022.

***Research conclusions***

Patients with UC experienced stress and worsened their symptoms in 2020 during the COVID-19 pandemic. The virus epidemic continued in 2021 and 2022, but the symptoms did not worsen.

***Research perspectives***

Since the symptoms of patients with UC are significantly worsened by stress, doctors need to pay attention to the worsening of symptoms of patients with ulcreative colitis when a major disaster occurs in the future.

**ACKNOWLEDGEMENTS**

We would like to thank Yoko Takamiya, Kaoru Aoki, Mika Sugimura, Kaori Oishi, and Maki Wakabayashi of Morio Clinic for preparing the patient lists.

**REFERENCES**

1 **Suda T**, Takahashi M, Katayama Y, Tamano M. COVID-19 pandemic and exacerbation of ulcerative colitis. *World J Clin Cases* 2021; **9**: 11220-11227 [PMID: 35071552 DOI: 10.12998/wjcc.v9.i36.11220]

2 **Ministry of Health Labour and welfare**. Visualizing the data: information on COVID-19 infections. 2023. [cited 1 July 2023]. Available from: https://covid19.mhlw.go.jp/en/

3 New coronavirus infections Report on the Implementation Status of the State of Emergency. October 2021. [cited 1 July 2023]. Available from: https://corona.go.jp/news/pdf/houkoku\_r031008.pdf

4 Public Notice on the Termination of Priority Measures to Prevent the Spread of Novel Coronavirus Infections.March 1, 2023. [cited 1 July 2023]. Available from: https://corona.go.jp/emergency/pdf/kouji\_20220317.pdf

5 **Wintjens DSJ**, de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, van Bodegraven AA, Mahmmod N, Markus T, Haans J, Masclee AAM, Winkens B, Jonkers DMAE, Pierik MJ. Novel Perceived Stress and Life Events Precede Flares of Inflammatory Bowel Disease: A Prospective 12-Month Follow-Up Study. *J Crohns Colitis* 2019; **13**: 410-416 [PMID: 30371776 DOI: 10.1093/ecco-jcc/jjy177]

6 **Sutherland LR**, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. *Gastroenterology* 1987; **92**: 1894-1898 [PMID: 3569765 DOI: 10.1016/0016-5085(87)90621-4]

7 **Matts SG**. The value of rectal biopsy in the diagnosis of ulcerative colitis. *Q J Med* 1961; **30**: 393-407 [PMID: 14471445]

8 **Kishi M**, Hirai F, Takatsu N, Hisabe T, Takada Y, Beppu T, Takeuchi K, Naganuma M, Ohtsuka K, Watanabe K, Matsumoto T, Esaki M, Koganei K, Sugita A, Hata K, Futami K, Ajioka Y, Tanabe H, Iwashita A, Shimizu H, Arai K, Suzuki Y, Hisamatsu T. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. *J Gastroenterol* 2022; **57**: 246-266 [PMID: 35235037 DOI: 10.1007/s00535-022-01862-y]

9 **Hagiwara SI**, Okayasu I, Fujiwara M, Matsuura M, Ohnishi H, Ito S, Kishimoto H, Nambu R, Kagimoto S. Prostaglandin E-major Urinary Metabolite as a Biomarker for Pediatric Ulcerative Colitis Activity. *J Pediatr Gastroenterol Nutr* 2017; **64**: 955-961 [PMID: 27906804 DOI: 10.1097/MPG.0000000000001477]

10 **Robillard R**, Saad M, Edwards J, Solomonova E, Pennestri MH, Daros A, Veissière SPL, Quilty L, Dion K, Nixon A, Phillips J, Bhatla R, Spilg E, Godbout R, Yazji B, Rushton C, Gifford WA, Gautam M, Boafo A, Swartz R, Kendzerska T. Social, financial and psychological stress during an emerging pandemic: observations from a population survey in the acute phase of COVID-19. *BMJ Open* 2020; **10**: e043805 [PMID: 33310814 DOI: 10.1136/bmjopen-2020-043805]

11 **Singh S**, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. *Gastroenterology* 2020; **158**: 1465-1496.e17 [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of Dokkyo Medical University Saitama Medical Center (Approval No. 20100).

**Informed consent statement:** All patients provided informed consent to participate in this study and agreed to publication of the research results.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** May 24, 2023

**First decision:** June 20, 2023

**Article in press:** July 25, 2023

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Choi YS, South Korea; Zhang C, China **S-Editor:** Chen YL **L-Editor:** A **P-Editor:** Chen YL

**Figure Legends**



**Figure 1** **Score.** A: Ulcerative colitis disease index score was exacerbated by the first wave of the coronavirus disease 2019 (COVID-19) pandemic as compared with those 1 and 2 years later. Ulcerative colitis disease activity index score exacerbated by the first wave of COVID-19 was significantly recovered a year later and remained or tended to be improved 2 years later despite pandemic persistence; B: Matts grade score, representing the pathological severity of colonic mucosa during the first wave of COVID-19 as compared with those 1 and 2 years later. Matts grade score was significantly recovered a year later and remained or tended to be improved 2 years later, despite pandemic persistence. UC-DAI: Ulcerative colitis disease activity index.

**Table 1 Characteristics of study participants from the 2020, 2021, and 2022 groups**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **2020 (*n* = 289)** | **2021 (*n* = 279)** | **2022 (*n* = 268)** |
| Age (yr) | 45.0 ± 15.8 | 45.13 ± 15.60 | 45.28 ± 15.40 |
| Sex (M/F) | 147/141 | 140/139 | 136/135 |
| Height (cm) | 163.6 ± 8.6 | 163.6 ± 8.6 | 163.7 ± 8.7 |
| Weight (kg) | 60.1 ± 11.3 | 60.1 ± 11.3 | 60.3 ± 11.1 |
| Disease duration (years) | 11.6 ± 8.5 | 11.50 ± 8.61 | 11.44 ± 8.40 |
| Smokers | 69 (23.8%) | 66 (23.6%) | 65 (24.2%) |
| Disease extent |  |  |  |
| Total colitis | 136 (47.0%) | 113 (40.5%) | 128 (47.7%) |

Originally, 289 consecutive patients visiting the clinic were included into the study in March and April 2020, representing the first wave of the coronavirus disease 2019 pandemic. Ten patients dropped out from the original study group in 2021 and additional 11 patients dropped out in 2022. However, no significant differences were seen among the three groups for weight, height, disease duration, smoker rate, sex, disease extent or total colitis rate.

**Table 2 Pharmacotherapies used for the 2020, 2021, and 2022 groups, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **2020 (*n* = 289)** | **2021 (*n* = 279)** | **2022 (*n* = 268)** |
| 5-ASA | 165 (57.0) | 158 (56.6) | 151 (56.3) |
| AZA or 6-MP | 35 (12.1) | 32 (11.4) | 33 (12.3) |
| IFX | 36 (12.4) | 35 (12.5) | 33(12.3) |
| ADA | 26 (8.9) | 26 (9.3) | 26 (9.7) |
| GLM | 9 (3.1) | 9 (3.2) | 7 (2.6) |
| VDZ | 0 (0) | 1 (0.3) | 1 (0.3) |
| UST | 0 (0) | 1 (0.3) | 1 (0.3) |
| TFN | 2 (0.6) | 2 (0.7) | 3 (1.1) |
| TF | 8 (2.7) | 8 (2.8) | 7 (2.6) |
| IR | 5 (1.7) | 5 (1.7) | 4 (1.0) |
| PSL | 1 (0.3) | 0 (0) | 1 (0.3) |
| CHM | 1 (0.3) | 1 (0.3) | 1 (0.3) |
| ND | 1 (0.3) | 1 (0.3) | 0 (0) |

5-ASA: Aminosalicylic acid; AZA: Azathioprine; 6-MP: Mercapton; IFX: Infliximab; ADA: Adalimumab; GLM: Golimumab; UST: Ustekinumab; TFN: Tofacitinib; VDZ: Vedolizmab; TF: Topical formulation; IR: Intestinal regulator; PSL: Prednisolone; CHM: Chinese herbal medicine; ND: No drug.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**